CRISPR Therapeutics AG - Common Stock (CRSP)

Q2 2020 13F Holders as of 6/30/2020

Type / Class
Equity / Common Stock
Shares outstanding
86M
Number of holders
259
Total 13F shares, excl. options
37.5M
Shares change
+3.47M
Total reported value, excl. options
$2.76B
Value change
+$288M
Put/Call ratio
1.19
Number of buys
145
Number of sells
-94
Price
$73.49

Significant Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q2 2020

325 filings reported holding CRSP - CRISPR Therapeutics AG - Common Stock as of Q2 2020.
CRISPR Therapeutics AG - Common Stock (CRSP) has 259 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 37.5M shares of 86M outstanding shares and own 43.67% of the company stock.
Largest 10 shareholders include ARK Investment Management LLC (6.48M shares), Versant Venture Management, LLC (4.18M shares), Nikko Asset Management Americas, Inc. (3.71M shares), NEA Management Company, LLC (2.09M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.38M shares), FEDERATED HERMES, INC. (1.08M shares), AMERIPRISE FINANCIAL INC (1.07M shares), FMR LLC (1.04M shares), WADDELL & REED FINANCIAL INC (1.03M shares), and BlackRock Inc. (1.01M shares).
This table shows the top 259 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
Investor Option Weight % Change % Value $ * Price $ Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.